학술논문
Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial
Document Type
Article
Author
Source
In: The Lancet Haematology . (The Lancet Haematology, March 2024, 11(3):e216-e227)
Subject
Language
English
ISSN
23523026